Effects of rivastigmine on motor and cognitive impairment in Huntington's disease.
To evaluate the efficacy of rivastigmine on motor and cognitive impairment in Huntington's disease (HD), we carried out a prospective, open-label, randomized, controlled study. Twenty-one HD patients were enrolled: 14 were randomly sorted into medication and 7 to no-treatment groups. Clinical and demographic features were similar between groups. After 8 months, an efficacy evaluation was carried out to compare the two groups. The improvement of cholinergic transmission in HD patients seemed to have a slight effect in ameliorating cognitive performance and slowing motor deterioration.
de Tommaso
Marina
M
Department of Neurological and Psychiatric Sciences, University of Bari, Bari, Italy. m.detommaso@neurol.uniba.it
Specchio
Nicola
N
Sciruicchio
Vittorio
V
Difruscolo
Olimpia
O
Specchio
Luigi Maria
LM
D000328:Adult; D000368:Aged; D003072:Cognition Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D003710:Demography; D005260:Female; D006801:Humans; D006816:Huntington Disease / Q000150:complications* / Q000188:drug therapy* / Q000235:genetics; D008297:Male; D008875:Middle Aged; D009069:Movement Disorders / Q000175:diagnosis / Q000453:epidemiology / Q000209:etiology*; D018696:Neuroprotective Agents / Q000627:therapeutic use*; D048448:Phenylcarbamates / Q000627:therapeutic use*; D011446:Prospective Studies; D000068836:Rivastigmine; D012720:Severity of Illness Index; D019680:Trinucleotide Repeat Expansion / Q000235:genetics
D018696:Neuroprotective Agents; D048448:Phenylcarbamates; D000068836:Rivastigmine